CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 54 enrolled
Drug / intervention
lipoic acid and omega-3 fatty acids +1 moredrug
Likely dose
lipoic acid and omega-3 fatty acids 1,200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02133664
NCT02133664Phase 2Completed
CompareCT.gov

Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

Oregon Health and Science University·interventional·Posted May 8, 2014·Updated Jun 2, 2017

In Brief

A Phase 2 clinical trial evaluating lipoic acid and omega-3 fatty acids and Placebo for Multiple Sclerosis and Cognition. Completed, enrolled 54 participants across 1 site.

Detailed Summary

The primary aim is to collect data to determine the correct effect size on the primary outcome to aid in the design of a larger study: The primary outcome is to determine if lipoic acid and omega-3 fatty acids can improve cognitive function in people with multiple sclerosis that have cognitive dysfunction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Cognition
CountriesUnited States
CollaboratorsNational Multiple Sclerosis Society

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 8, 2014
Enrollment StartJun 1, 2014
Primary CompletionMay 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 12.2 years ago

Interventions

lipoic acid and omega-3 fatty acidsdrug

alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid

Placebodrug

placebo lipoic acid and placebo oil